CELLECTIS
LIVE

Serial Number

79243427

Owner

CELLECTIS

Attorney

Mary Margaret L. O'Donnell

Filing Date

Apr 6, 2018

Add to watchlist:

No watchlists yet
View on USPTO

CELLECTIS Trademark

Serial Number: 79243427 • Registration: 6202570

CELLECTIS is a trademark filed by CELLECTIS on April 6, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

CELLECTIS (10 trademarks)

102 avenue Gaston Roussel

Entity Type: 99

Trademark Details

Filing Date

April 6, 2018

Registration Date

November 24, 2020

Published for Opposition

September 8, 2020

Goods & Services

Technical studies and evaluation of new products in the pharmaceutical industry; engineering services; computer programming; Design and development of computer software and hardware; scientific and industrial research in the agri-food, horticulture and agriculture sector for genome modification of cells of all types; genetic, medical and pharmaceutical research; research in chemistry, biology, biochemistry, molecular biology or bacteriology; research and development in biochemical analysis, biological analysis and molecular biology techniques; Research and development of new compounds for use in industry, agriculture and horticulture; scientific laboratory services

Pharmaceutical products for the treatment of cancer, immune system related diseases and disorders; microorganism cultures and nutritive substances for microorganism cultures for medical and pharmaceutical use; bacteriological preparations for medical and pharmaceutical use; biological preparations for medical and pharmaceutical use for treating cancer, immune system or genetic diseases or disorders, and malnutrition; chemical and biochemical preparations for medical, pharmaceutical, and therapeutic use for treating cancer and malnutrition; micro-organism preparations and cultures for medical, pharmaceutical and veterinary purposes; health food, beverages, preparations and substances, namely, dietetic foods for the treatment of celiac disease, nutritional supplements, medical preparations and substances for treatment of malnutrition, cancer, high cholesterol, cardiovascular disease, diabetes, coronary heart disease, immune system related diseases and disorders, nutritionally fortified beverages for medical purposes; plant-based health-food substances, namely, dietetic foods, namely, edible oils and fats, processed fruits and vegetables, preserved, dried and cooked fruits and vegetables, potato based snack food, soybeans based snack food, potato crisps, potato flakes and potato fritters, potato fries, cooked ready meals consisting primarily of vegetables, soya crisps, soya flakes, soya fries, corn-based snack food, wheat based snack foods, oat based snack foods, alfalfa based snack foods, coffee, coffee substitutes, seasonings, sauces and condiments, namely, mustard, ketchup and other tomatoes sauces, cooked ready meals consisting primarily of pasta or rice, potato, soya, corn, wheat, alfalfa or oat based foods, namely, puree, corn, wheat, alfalfa or oat crisps, soya, corn, wheat, alfalfa and oat flour, corn, wheat, alfalfa and oat flakes, corn, wheat, alfalfa and oat fries, adapted for medical use; dietary supplements; nutritional supplements; nutritional additives in the nature of dietary and nutritional supplements for medical purposes; cultures and preparations of micro-organisms for medical or therapeutic, pharmaceutical and veterinary use, namely, human and animal cells in the nature of biological tissue cultures for the treatment of cancer, immune system related diseases and disorders; bacteriological preparations for in vivo and in vitro genetic engineering, for medical, pharmaceutical and veterinary purposes; medicines for veterinary use for treating cancer and malnutrition; medicines for human use for treating cancer and malnutrition; Diagnostic preparations for the treatment of cancer, immune system related diseases and disorders, malnutrition; Pharmaceutical products for medical purposes in the nature of enzymes, namely, natural and engineered nucleases, nucleic acid vectors, molecular scissors; Chemical and pharmaceutical products for medical purposes in the nature of enzymes, namely, natural and engineered nucleases, nucleic acid vectors and molecular scissors; Veterinary products, namely, nucleic acid sequences being enzymes, stem cells, chemical and biological reagents, bacteria, yeasts, enzymes, bacteriological preparations, natural and engineered endoncucleases being enzymes

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 24, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Oct 28, 2023 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 18, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 18, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 18, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 18, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 18, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 18, 2023 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 14, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 24, 2021 FICS
FINAL DISPOSITION PROCESSED
Feb 24, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 24, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 24, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 8, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 8, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Sep 5, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 19, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 19, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 19, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 3, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 3, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 3, 2020 CRFA
ASSIGNED TO LIE
Jul 27, 2020 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 24, 2020 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 3, 2020 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 18, 2020 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 18, 2020 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 31, 2020 GNFN
FINAL REFUSAL E-MAILED
Jan 31, 2020 GNFR
FINAL REFUSAL WRITTEN
Jan 31, 2020 CNFR
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 10, 2020 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 10, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 13, 2019 CRFA
ASSIGNED TO LIE
Dec 11, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2019 TROA
REFUSAL PROCESSED BY IB
Jun 28, 2019 RFNT
NON-FINAL ACTION MAILED
May 30, 2019 CNRT
NON-FINAL ACTION WRITTEN
May 29, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 8, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 7, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 7, 2019 TROA
REFUSAL PROCESSED BY IB
Dec 8, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 16, 2018 RFCS
REFUSAL PROCESSED BY MPU
Nov 15, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 31, 2018 RFCR
NON-FINAL ACTION WRITTEN
Oct 30, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 27, 2018 MAFR
ASSIGNED TO EXAMINER
Oct 23, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 23, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 18, 2018 REPR